FDA Clears MammoScreen™ from Therapixel
Artificial intelligence tool designed to improve radiologist cancer detection performance.
Therapixel captured 510(k) clearance from the U.S. Food and Drug Administration this week for MammoScreen™, an explainable, actionable artificial intelligence (AI) tool designed to help with mammography interpretation.
The clearance comes after the release of findings from a multi-case study, company officials said, that showed radiologists had better cancer detection performance on mammograms when they used MammoScreen versus when they analyzed images solo.
“We believe MammoScreen will provide quick and reliable confirmation of radiologists’ suspicions as they read,” said Matthieu Leclerc-Chavlet, Therapixel chief executive officer. “This AI solution will ensure a more certain assessment by radiologists and a speedier reassurance of women having breast cancer screening exams, resulting in a more efficient workflow and reduced costs for the healthcare system.”
According to company information, MammoScreen can automatically detect and characterize suspicious soft tissue lesions and calcifications on mammography images while simultaneously assessing their likelihood of malignancy. Radiologists receive a summary report that categorizes each lesion’s suspiciousness on a scale of 1-to-10 with 10 being the most likely to indicate malignancy.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
